Pharmaceutical companies face increasing pressure from a variety of stakeholders, including patients, physicians, public and private payers and the federal government to lower drug costs. The Patient Protection and Affordable Care Act exemplifies the national perception that pharmaceutical companies must lower the costs of therapies in order to decrease the burden on patients. This sentiment creates additional challenges for reimbursement and market access executives as manufacturers attempt to effectively present the value their products bring in advancing the healthcare landscape. This session will provide attendees with oversight for developing, communicating and capturing value in a way that ensures that payers recognize the value that a treatment offers.
- Creating and supporting product value through evidence development
- Incorporating cost-effectiveness into value propositions
- Methods for identifying points of differentiation versus existing standards of care
Director of Market Access
Xcenda, an AmerisourceBergen Company